# A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

> **NCT07510594** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Large-Cell Neuroendocrine Carcinoma of the Lung
- Extrapulmonary Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Benmelstobart+ Anlotinib+ Platinum + Etoposide

## Key facts

- **NCT ID:** NCT07510594
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510594, "A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07510594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*